347 Real-World Outcomes in Patients Implanted With DBS Systems Capable of Directionality and Multiple Independent Current Control

View at publisher Summarise with VIRAT
Authors: Michael S. Okun, Kelly D. Foote, Theresa Zesiewicz, Yarema B. Bezchlibnyk, Alexander Papanastassiou, Okeanis Vaou, Jonathan Dennis Carlson, Jason L. Aldred, Vibhor Krishna, Brian Dalm, Corneliu C. Luca, Jonathan Russell Jagid
+16 more Julie G. Pilitsis, Jennifer Durphy, Leo Verhagen-Metman, Sepehr Sani, Steven G. Ojemann, Drew S. Kern, David B. Weintraub, Ritesh Ramdhani, Abdolreza Siadati, Bharathy Sundaram, Cong Zhi Zhao, Derek L Martinez, Mustafa Siddiqui, Stephen B. Tatter, Lilly Chen, Edward Goldberg
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Tracking those being treated for Parkinson's disease (PD) motor symptoms offers insight regarding the outcomes associated with the implanted Deep Brain Stimulation (DBS) systems that are utilized by patients in the real-world clinical setting. METHODS: Prospectively-enrolled participants were implanted with Vercise DBS systems (Boston Scientific), a multiple-source, constant-current system, and assessed up to 3-years post-implantation as part of an on-going DBS patient outcomes registry (clinicaltrials.gov identifier: NCT02071134). Clinical measures recorded at baseline and during follow-up included MOS-Unified Parkinson's disease Rating Scale (MDS-UPDRS), Parkinson's Disease Questionnaire (PDQ-39), Global Impression of Change (GI(), and the Non-Motor Symptom Assessment Scale (NMSS). Adverse events and device-related complications are also collected. RESULTS: Enrollment and device activation consists of 174-subjects (mean age: 64.2 ± 8.7 years, 68.5% male, disease duration 9.3 ± 5.1 years, n = 168) and 142-subjects, respectively. Assessment of MDS-UPDRS Ill in “off” medication condition demonstrated a 51% improvement (25-points, p < 0.0001) in motor function at 6-months. This level of motor function improvement was maintained out to 1-year (22-point improvement) and to 2-years (24-point improvement) follow-up. As compared with baseline, over 93% of patients and over 89% of clinicians noted improvement (GIC) at 6-, 12-, and 24-months follow-up. Outcomes were improved in various quality life measures (PDQ-39): mobility, activities of daily living, bodily discomfort, emotional well-being, and stigma. To date, no lead fractures or unanticipated adverse events were reported. Additional results derived from on-going data collection will be presented. CONCLUSIONS: Following DBS, outcomes derived from this on-going multicenter, prospective registry demonstrated improved motor function, quality-of-life, and satisfaction. This on-going registry will continue to provide insight regarding application of MICC-based directional DBS systems for PD as applied in real-world settings.

Fields of Study & Subjects

Deep Brain Stimulation and Movement Disorders Obsessive-Compulsive Spectrum Disorders Botulinum Toxin and Related Neurological Disorders

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
92–93
Publication date
26 March 2026
Language
EN